Insmed Incorporated (NASDAQ:INSM) Stock Holdings Increased by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC boosted its position in Insmed Incorporated (NASDAQ:INSM) by 65.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 413 shares of the biopharmaceutical company’s stock after buying an additional 163 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Insmed were worth $29,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of INSM. V Square Quantitative Management LLC grew its holdings in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management bought a new position in shares of Insmed during the fourth quarter valued at approximately $47,000. Smartleaf Asset Management LLC grew its holdings in shares of Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 411 shares during the last quarter. Venturi Wealth Management LLC bought a new position in shares of Insmed during the fourth quarter valued at approximately $86,000. Finally, Quantbot Technologies LP bought a new position in shares of Insmed during the third quarter valued at approximately $133,000.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 6,172 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08. Following the completion of the sale, the insider now owns 101,549 shares in the company, valued at approximately $6,462,578.36. This represents a 5.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the sale, the chief executive officer now owns 334,186 shares of the company’s stock, valued at $25,742,347.58. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 550,957 shares of company stock worth $42,992,528 over the last ninety days. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $100.00 target price on shares of Insmed in a report on Wednesday. Morgan Stanley upped their target price on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. UBS Group upped their target price on Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, March 6th. HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, February 21st. Finally, Stifel Nicolaus reduced their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $93.33.

Insmed Stock Performance

INSM opened at $78.94 on Thursday. The company has a market capitalization of $14.29 billion, a price-to-earnings ratio of -14.12 and a beta of 1.28. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The business has a 50 day moving average price of $76.88 and a two-hundred day moving average price of $73.74.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Research analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.